Soy-Based Infant Formulas: A Review of Developmental and Nutritional Considerations

Neither soyfoods nor isoflavones warrant classification as endocrine disruptors: a technical review of the observational and clinical data

“…Pharmacokinetic studies show that peak plasma level (C max ) is achieved faster when aglycones as opposed to glucosides are consumed (Setchell et al 2001;Izumi et al 2000;Kano et al 2006;Cassidy et al 2006). C max may also be higher, but whether total isoflavone absorption is greater in response to the ingestion of aglycones vs glycosides is unclear as the data are quite conflicting with some studies showing no difference in urinary isoflavone excretion between fermented and unfermented foods or glycosides and aglycones (Zubik and Meydani 2003;Beeson et al 1989;Butler et al 2008;Davey et al 2003;Messina 2004;Patisaul, Fenton, and Aylor 2018;Jocsak et al 2019;Setchell et al 2011;Vandenplas et al 2014;Testa et al 2018;Jefferson, Patisaul, and Williams 2012;Badger et al 2009;Stevens 2017;McCarver et al 2011;Bhatia and Greer 2008;Badger et al 2002;Yilmaz et al 2020;WHO & UNEP 2013;Soy Infant Formula 2019;Boucher et al 2008;Murphy et al 1999;Vieux, Maillot, and Rehm 2020;Yang et al 2005;Shu et al 2015;Liu et al 2004;Lee and Kim 2007;Kim et al 2015;Talaei et al 2014;Mueller et al 2012;Ho et al 2003;Koh et al 2005;Tai et al 2012;Dixon and Sumner 2003;Barnes et al 2002;…”

“…1. SIF has been extensively reviewed by previous authors (Vandenplas et al 2014;Testa et al 2018;Jefferson, Patisaul, and Williams 2012;Badger et al 2009;Stevens 2017) and committees (McCarver et al 2011;Bhatia and Greer 2008). 2.…”